- Home
- TGLS vs MRUS Comparison
TGLS vs MRUS Comparison
Compare TGLS & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGLS
- MRUS
- Stock Information
- Founded
- TGLS 1984
- MRUS 2003
- Country
- TGLS Colombia
- MRUS Netherlands
- Employees
- TGLS N/A
- MRUS N/A
- Industry
- TGLS Electronic Components
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- TGLS Consumer Discretionary
- MRUS Health Care
- Exchange
- TGLS Nasdaq
- MRUS Nasdaq
- Market Cap
- TGLS 3.7B
- MRUS 3.6B
- IPO Year
- TGLS 2012
- MRUS 2016
- Fundamental
- Price
- TGLS $73.15
- MRUS $46.58
- Analyst Decision
- TGLS Buy
- MRUS Strong Buy
- Analyst Count
- TGLS 5
- MRUS 10
- Target Price
- TGLS $75.40
- MRUS $86.70
- AVG Volume (30 Days)
- TGLS 341.8K
- MRUS 376.4K
- Earning Date
- TGLS 11-07-2024
- MRUS 10-31-2024
- Dividend Yield
- TGLS 0.60%
- MRUS N/A
- EPS Growth
- TGLS N/A
- MRUS N/A
- EPS
- TGLS 3.20
- MRUS N/A
- Revenue
- TGLS $845,211,000.00
- MRUS $35,932,000.00
- Revenue This Year
- TGLS $8.70
- MRUS N/A
- Revenue Next Year
- TGLS $11.18
- MRUS $52.49
- P/E Ratio
- TGLS $22.88
- MRUS N/A
- Revenue Growth
- TGLS N/A
- MRUS N/A
- 52 Week Low
- TGLS $33.19
- MRUS $22.26
- 52 Week High
- TGLS $80.51
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- TGLS 53.73
- MRUS 32.37
- Support Level
- TGLS $70.24
- MRUS $48.42
- Resistance Level
- TGLS $75.30
- MRUS $53.49
- Average True Range (ATR)
- TGLS 2.64
- MRUS 2.17
- MACD
- TGLS 0.16
- MRUS -0.54
- Stochastic Oscillator
- TGLS 47.91
- MRUS 5.73
About TGLS Tecnoglass Inc.
Tecnoglass Inc designs, manufactures, distributes, and markets architectural glass and windows. The company's products portfolio includes tempered, laminated, insulating and Solar Control Low-E glass. Its products are installed at hotels, residential buildings, commercial and corporate centers, airports and hospitals as floating facades, curtain walls, windows, doors, handrails, interior and dividers. Its majority of revenue is derived from the sale and installation of architectural glass and windows in the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.